{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:20:47Z","timestamp":1781601647531,"version":"3.54.5"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,19]]},"abstract":"<jats:p>As a common treatment for rheumatoid arthritis (RA), the adverse reactions of TNF-\u03b1 inhibitors (TNFis) in practical application have garnered attention. This study aims to investigate the adverse drug events (ADEs) associated with TNFi in RA patients as reported in the FDA Adverse Event Reporting System, to offer insights for clinical use. Cases related to RA and primarily involving TNFi were extracted from the FDA Adverse Event Reporting System database and compared by gender stratification. Screening was conducted based on reporting odds ratio and information component to identify positive ADEs for different TNFis and evaluate common and unique ADEs among various TNFis. There are 4 common ADEs among TNFis, including pulmonary tuberculosis, infection, hypersensitivity, and herpes zoster, as described in the package inserts. However, each TNFi has unique positive ADEs. Adalimumab has 63 unique positive ADEs, including lower respiratory tract inflammation, systemic lupus erythematosus rash, vascular dementia, ovarian neoplasm, adhesion, sarcoma, coccidioidomycosis, etc. Golimumab has 6 unique positive ADEs, including pneumonia cryptococcal, device deployment issue, pneumonia bacterial, polyneuropathy, device malfunction, device issue, etc; certolizumab has 24 unique positive ADEs, including maternal exposure before pregnancy, premature rupture of membranes, exposure via breast milk, staphylococcal sepsis, erysipelas, low birth weight baby, herpes virus infection, premature delivery, etc; etanercept has 180 unique positive ADEs, including joint destruction, chondrolysis, finger deformity, ankle deformity, joint warmth, etc; infliximab has 60 unique positive ADEs, including Hodgkin\u2019s disease, metastatic neoplasm, non-Hodgkin\u2019s Lymphoma, etc. Although the aforementioned 5 TNFis share common ADEs such as herpes zoster, clinicians must exercise caution when selecting specific medications, especially for RA patients concurrently suffering from malignancies. The analysis indicates that infliximab is associated with 60 unique positive ADEs, including Hodgkin\u2019s disease, metastatic neoplasm, and non-Hodgkin\u2019s lymphoma; therefore, these patients should use infliximab with greater caution. Similarly, certolizumab should be used with increased caution in pregnant and postpartum women.<\/jats:p>","DOI":"10.1097\/md.0000000000039012","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:14:01Z","timestamp":1721434441000},"page":"e39012","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Safety of TNF-\u03b1 inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database"],"prefix":"10.1097","volume":"103","author":[{"given":"Bohui","family":"Zheng","sequence":"first","affiliation":[{"name":"Clinical Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manting","family":"Liu","sequence":"additional","affiliation":[{"name":"Clifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Dai","sequence":"additional","affiliation":[{"name":"The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Shang","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Dou","sequence":"additional","affiliation":[{"name":"The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingshuo","family":"Liu","sequence":"additional","affiliation":[{"name":"The Fifth Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilan","family":"Zhong","sequence":"additional","affiliation":[{"name":"The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Huang","sequence":"additional","affiliation":[{"name":"General Hospital of Guangzhou Military Command of PLA, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-0182","authenticated-orcid":false,"given":"Dongqiang","family":"Luo","sequence":"additional","affiliation":[{"name":"Clifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events.","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.gastro.2014.09.031","article-title":"Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn\u2019s disease after surgery: a systematic review and network meta analysis.","volume":"148","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet (London, England)"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1097\/MIB.0000000000000533","article-title":"New insights into the mechanisms of action of anti-tumor necrosis factor-\u03b1 monoclonal antibodies in inflammatory bowel disease.","volume":"21","author":"Slevin","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","article-title":"Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.","volume":"50","author":"Dusetzina","year":"2012","journal-title":"Med Care"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications.","volume":"287","author":"Lasser","year":"2002","journal-title":"JAMA"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2105\/AJPH.2007.124537","article-title":"Adverse event detection in drug development: recommendations and obligations beyond phase 3.","volume":"98","author":"Berlin","year":"2008","journal-title":"Am J Public Health"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jcpt.12393","article-title":"Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects.","volume":"41","author":"Varela","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5414\/CP202171","article-title":"Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.","volume":"53","author":"Borr\u00e1s-Blasco","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MAJ.0b013e3182926a23","article-title":"Efficacy of antitumor necrosis factor(\u03b1) agents on patients with ankylosing spondylitis.","volume":"346","author":"Ren","year":"2013","journal-title":"Am J Med Sci"},{"key":"R11-20250503","article-title":"Electronic medicines compendium (EMC)[EB\/OL].","author":"Limited","year":"2023"},{"key":"R12-20250503","article-title":"Electronic medicines compendium (EMC)[EB\/OL].","author":"Limited","year":"2023"},{"key":"R13-20250503","article-title":"Electronic medicines compendium (EMC)[EB\/OL].","author":"Limited","year":"2023"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2147\/TCRM.S38852","article-title":"Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab.","volume":"9","author":"Freeman","year":"2013","journal-title":"Therap Clin Risk Manag"},{"issue":"PtA","key":"R15-20250503","doi-asserted-by":"crossref","first-page":"107049","DOI":"10.1016\/j.intimp.2020.107049","article-title":"Tumor necrosis factor inhibitor-induced pleuropericarditis: a retrospective evaluation using data from VigiBase.","volume":"89","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40264-022-01210-2","article-title":"Anti-tumor necrosis factor-alpha therapy and hypoglycemia: a real-world pharmacovigilance analysis.","volume":"45","author":"Zhou","year":"2022","journal-title":"Drug Saf"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"e003912","DOI":"10.1136\/rmdopen-2023-003912","article-title":"\u201cRisk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b\/4 randomised safety study\u201d.","volume":"10","author":"Buch","year":"2024","journal-title":"RMD Open"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/ajcp\/110.5.615","article-title":"Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics.","volume":"110","author":"Choudhry","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil--free eyeballs on AERS pharmacovigilance data.","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat Biotechnol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications.","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajg.2022.10.012","article-title":"Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: Adisproportionality analysis in FDA adverse event reporting system (FAERS) database.","volume":"24","author":"Nair","year":"2023","journal-title":"Arab J Gastroenterol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1080\/14740338.2021.1962846","article-title":"Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.","volume":"20","author":"Singh","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source.","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"\u201cInflammation and tumor progression: signaling pathways and targeted intervention\u201d.","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/kep095","article-title":"Promoting science over serendipity in prescribing anti-TNF therapy.","volume":"48","author":"Chee","year":"2009","journal-title":"Rheumatology (Oxford, England)"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/keaa636","article-title":"Risk factors for herpes zoster inpatients with rheumatic diseases: a nationwide cohort study in Korea.","volume":"60","author":"Ryu","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1038\/s41598-022-07968-w","article-title":"TNF inhibitors increase the risk of nontuberculous mycobacteria inpatients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area.","volume":"12","author":"Park","year":"2022","journal-title":"Sci Rep"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s10067-020-05045-z","article-title":"Is Takayasu arteritis the result of a Mycobacterium tuberculosis infection? The use of TNF inhibitors maybe the proof-of-concept to demonstrate that this association is epiphenomenal.","volume":"39","author":"Castillo-Mart\u00ednez","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"e034356","DOI":"10.1136\/bmjopen-2019-034356","article-title":"Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.","volume":"10","author":"Rotar","year":"2020","journal-title":"BMJ Open"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/bmjopen-2012-001395","article-title":"A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoidarthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years.","volume":"2","author":"Jobanputra","year":"2012","journal-title":"BMJ Open"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"102942","DOI":"10.1016\/j.msard.2021.102942","article-title":"Use of anti-TNF-\u03b1 therapy in Crohn\u2019s disease is associated with increased incidence of multiple sclerosis.","volume":"51","author":"Avasarala","year":"2021","journal-title":"Mult SclerRelat Disord"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5152\/eurjrheum.2018.17193","article-title":"First case of demyelinatingpolyneuropathy probably related to treatment with golimumab.","volume":"5","author":"D\u00edez","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5114\/ada.2020.102089","article-title":"The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: areview of current clinical guidelines.","volume":"37","author":"Owczarek","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"727739","DOI":"10.1111\/bcp.12642","article-title":"Pregnancy outcome after TNF-\u03b1 inhibitor therapy during the first trimester: a prospective multicentre cohort study.","volume":"80","author":"Weber-Schoendorfer","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"105","DOI":"10.55563\/clinexprheumatol\/j9ysbm","article-title":"Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy.","volume":"39","author":"Prieto-Pe\u00f1a","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/pds.4695","article-title":"Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.","volume":"28","author":"Eworuke","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R40-20250503","first-page":"1","article-title":"Management of psoriasis in pregnancy - a review of the evidence to date.","volume":"9","author":"Ferreira","year":"2020","journal-title":"Drugs Context"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1017\/erm.2022.18","article-title":"TNF-\u03b1\/anti-TNF-\u03b1 drugs and its effect on pregnancy outcomes.","volume":"24","author":"Dai","year":"2022","journal-title":"Expert Rev Mol Med"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L","article-title":"The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.","volume":"44","author":"Welsing","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R43-20250503","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.11487","article-title":"Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.","volume":"50","author":"Zwerina","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.20775","article-title":"Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/rheumatology\/kes188","article-title":"Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT)study.","volume":"51","author":"Tada","year":"2012","journal-title":"Rheumatology (Oxford, England)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:33:10Z","timestamp":1746318790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":44,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039012","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]}}}